Mylosar review

Mylosar is used to treat myelodysplastic syndrome (Myelodysplastic syndromes), a type of bone marrow disease that typically precedes leukemia, and its subtypes such as various refractory anaemia, including those with ringed sideroblasts, excess blasts, and excess blasts in transformation. Myelodysplastic syndromes is caused by the improper functioning of the bone marrow. When bone marrow cells are deformed, this causes a decrease in blood production. It is also used in the treatment of some leukemia such as chronic myelomonocytic leukemia, refractory acute lymphocytic leukemia and refractory acute myelogenous leukemia

Mylosar improves the bone marrow function by binding to the DNA and RNA, and improving blood production by killing off abnormal cells. In a study done on Mylosar use, patients that previously needed blood transfusions for Myelodysplastic syndromes no longer needed it after being treated with Mylosar, and 16% reported full return of bone marrow structure and blood cell count.

Mylosar is available as a powder, readily soluble in water and can be administered subcutaneously or intravenously by a physician or nurse. Treatment is typically a once-a-day injection for seven days, and may be repeated after 4 weeks. Physicians typically prescribe 4 treatments at a time. However, doses may be increased after two cycles if significant improvement is not evident and no adverse side effects are seen. Alternatively, subsequent treatments may be delayed or doses reduce if adverse side effects are evident. It is important to communicate with your physician regarding any symptoms felt while undergoing treatment. The dose is dependent on the patient's weight, previous treatment history and other assessments made by your physician. The physician may also use Mylosar in other related conditions if found to work effectively.

Known side effects may include nausea, diarrhea or constipation, mouth sores, tiredness, cramps, back and joint pain, perspiration, skin edema of ankles, hands and feet, rashes and reddening of skin and weakness. If you experience any of these conditions, consult your physician.

A low white blood count may be experienced in between sessions. During this period you may be susceptible to infections. This low point is temporary, lasting usually 10-17 days but possibly taking 28-31 days to recover.

Serious side effects that require immediate medical attention include pale skin, rapid heartbeat, chest pains, bruising or bleeding, epistaxis, signs of infection such as a fever and sore throat, and red or purple dots on the skin. Consult your physician immediately if any of these side effects occur.

Make certain that your physician is aware of any medications you are currently taking as well as any medication allergies you have. Also, avoid taking aspirin while undergoing treatment unless your physician specifically allows this.

Do not take any form of immunization such as vaccines while on Mylosar. The lowered white blood cell count may leave you in danger.

Mylosar may be harmful to a developing fetus if you are pregnant and may also affect fertility if you are planning to become pregnant. Contraceptives may also interact with the medication so barrier methods such as condoms are advised while taking this medication. Avoid breastfeeding during this period as well. Consult your physician for additional information.

Mylosar has the following structural formula:

Chemical structure of mylosar

• Molecular formula of mylosar is C8H12N4O5
• Chemical IUPAC Name is 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
• Molecular weight is 244.205 g/mol
Mylosar available : 100mg tablets

Generic name: Azacitidine

Brand name(s): Azacitidina, Azacitidinum, Azacytidine, Ladakamycin, Vidaza

  Your Mylosar review